- |||||||||| Review, Journal: Expert Consensus on the Systemic Treatment of Atopic Dermatitis in Special Populations. (Pubmed Central) - May 15, 2023
A modified Delphi process was used to arrive at a set of final consensus statements related to the systemic treatment of AD in these specific patient populations. To provide practical guidance on the choice of systemic therapy for atopic dermatitis in these six topics of clinical interest, 25 expert consensus statements and a summary of the supporting data are presented herein.
- |||||||||| Review, Journal: Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence. (Pubmed Central) - May 14, 2023
Physicians who treat patients with AD with Jak inhibitors and biologics need to understand the current evidence and choose the best treatment for individual patients. In this review, we discuss how integrating knowledge of the mechanisms of action of Jak inhibitors and biologics, the potential significant adverse events of these drugs, and the age and comorbidities of the patient can help achieve optimal clinical benefit for patients with moderate-to-severe AD refractory to topical agents.
- |||||||||| Review, Journal: "The Evolving Landscape of Immunotherapy for the Treatment of Allergic Conditions". (Pubmed Central) - May 12, 2023
As biologics become more targeted, fewer off-target effects are seen improving tolerability for patients as well as expanded options for treatment of these conditions. This review discusses monoclonal antibody therapies (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, tralokinumab) including their safety and use in asthma, chronic urticaria, atopic dermatitis, and eosinophilic esophagitis.
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed: Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA) (clinicaltrials.gov) - May 6, 2023
P3, N=130, Active, not recruiting,
This review discusses monoclonal antibody therapies (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, tralokinumab) including their safety and use in asthma, chronic urticaria, atopic dermatitis, and eosinophilic esophagitis. Recruiting --> Active, not recruiting
- |||||||||| Review, Journal: How to Understand Personalized Medicine in Atopic Dermatitis Nowadays? (Pubmed Central) - May 2, 2023
We have now reached the point of creating new strategies and AD treatment goals by increasing the amount of new information concerning the efficacy and safety of new drugs. This article has reviewed the novel treatment options for AD in the light of the heterogeneity of this disease and proposes a broader vision on the strategy of personalized treatment of AD.
- |||||||||| Reduction in topical corticosteroids prescribed post immunomodulatory systemic treatment initiation in moderate-to-severe atopic dermatitis: a retrospective real-world chart analysis (Poster Zone C) - Apr 30, 2023 - Abstract #EAACI2023EAACI_1146;
Method Patients receiving systemic treatment (dupilumab, tralokinumab, baricitinib, upadacitinib or abrocitinib) for AD as standard care in the Department of Dermatology of the University Hospital Jena were reviewed...TCS prescribed prior and post-systemic treatment were mainly methylprednisolone aceponate 0,1% (45.7% prior vs. 76.8% post), mometasone furoate 0,1% (27.6% prior vs. 17.9% post) and betamethasone valerate 0,1% (22.9% prior vs. 1.9% post), all potent TCS (group III) according to WHO...Due to retrospective study design, data was available for analysis only for a limited number of cases and primarily for subjects treated with dupilumab. Further prospective studies should be conducted to assess TCS sparing effect of immunomodulatory systemic treatments for AD.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Biologics in the management of childhood atopic dermatitis. (Pubmed Central) - Mar 7, 2023
Our findings indicate specific targeting of the interleukin 13 cytokine with tralokinumab can directly and/or indirectly improve microbial dysbiosis seen in AD skin. No abstract available
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Tralokinumab improves signs, symptoms, and key biomarkers in patients of different racial subgroups with atopic dermatitis (Room F (Harmony) ) - Mar 4, 2023 - Abstract #ISID2023ISID_300;
P3
In skin, gene expression of IL13RA1, IL4R, CCL2, and DPP4 was higher in Asian compared to White patients. Tralokinumab shifted biomarker expression, reduced S. aureus abundance, and improved signs/symptoms of AD across all racial subgroups over 16 weeks.
- |||||||||| Review, Journal: Efficacy of biologic therapy on airway hyperresponsiveness in asthma. (Pubmed Central) - Feb 26, 2023
In contrast, there have comparatively been fewer studies investigating the efficacy of biologics in AHR. In this focussed review, we summarise the existing evidence base in this area in regard to omalizumab, mepolizumab, benralizumab, tralokinumab and tezepelumab.
- |||||||||| Review, Journal: Targeting Interleukin 13 for the Treatment of Atopic Dermatitis. (Pubmed Central) - Feb 25, 2023
It is important for dermatologists to be aware of the evidence behind this emerging class of biologic agents to guide treatment choices and improve outcomes in patients with AD. The main objective of this paper is to review the current literature regarding the efficacy and safety of current and emerging anti-IL-13 monoclonal antibodies, including tralokinumab, lebrikizumab, cendakimab, and eblasakimab, for the treatment of moderate-to-severe AD.
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion date, Trial primary completion date: Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA) (clinicaltrials.gov) - Feb 8, 2023
P3, N=130, Recruiting,
The main objective of this paper is to review the current literature regarding the efficacy and safety of current and emerging anti-IL-13 monoclonal antibodies, including tralokinumab, lebrikizumab, cendakimab, and eblasakimab, for the treatment of moderate-to-severe AD. Trial completion date: May 2023 --> Oct 2023 | Trial primary completion date: Jan 2023 --> Jul 2023
- |||||||||| Journal: Atopic Dermatitis in Childhood and Adolescence: Diagnosis and Treatment. (Pubmed Central) - Feb 8, 2023
Trial completion date: May 2023 --> Oct 2023 | Trial primary completion date: Jan 2023 --> Jul 2023 A combination of baseline therapy, reactive and proactive anti-inflammatory therapy, and systemic therapy as needed is the foundation of successful interdisciplinary treatment for atopic dermatitis.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
IL-13 inhibition used for atopic diseases is associated with risk of psoriatic arthritis () - Feb 4, 2023 - Abstract #BSR2023BSR_340;
These findings are compatible with the hypothesis that Th2 cytokines IL-4/-13 may act as a restraint toward Th17-type disease activation in some organs. Clinicians assessing adverse events after dupilumab initiation should be aware of incident PsA and related features.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Journal: Safety of tralokinumab in atopic dermatitis. (Pubmed Central) - Jan 27, 2023
Clinicians assessing adverse events after dupilumab initiation should be aware of incident PsA and related features. No abstract available
- |||||||||| Review, Journal: Risks and safety of biologics: A practical guide for allergists. (Pubmed Central) - Jan 26, 2023
Our review focuses on the risk of hypersensitivity reactions, pregnancy-specific considerations, risk of infection and risk of malignancy. We also highlight drug-specific adverse events and unique safety issues identified in case reports.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Review, Journal: The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective. (Pubmed Central) - Jan 20, 2023
New biologic therapies in development, however, target different Th2-pathway molecules along with cytokines in other immune axes, including Th17 and Th22, offering promise for varied treatments for this heterogeneous disease. As the biologic pipeline advances, the integration into clinical practice and approval of these experimental biologics may provide more effective, tailored therapeutic solutions and illuminate on the pathologic processes of AD across a broader, more diverse patient population.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Journal: Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults. (Pubmed Central) - Jan 20, 2023
It was recently approved by Health Canada and the US FDA for the treatment of moderate-to-severe AD in adults and may be used alone or with topical corticosteroids. Herein, we review the efficacy and safety of tralokinumab in adults, as demonstrated in clinical trials.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Journal: IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis. (Pubmed Central) - Jan 18, 2023
A substantial proportion of patients with EASI<16 featured high biomarker levels suggesting systemic impact of skin inflammation already below the current cut-off for systemic therapy. Our findings facilitate the identification of patients with distinct endotypes potentially linked to response to IL-13-targeted therapy.
- |||||||||| Review, Journal: Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives. (Pubmed Central) - Dec 24, 2022
In addition, as available monoclonal antibody treatments have shown little benefit among patients with T-low asthma, research continues in this area, with several antibodies in development. This article summarizes the available pre-clinical and clinical data on new and emerging drugs for treating severe asthma, discusses discontinued treatments and outlines future directions in this area.
- |||||||||| U012 - Practical Considerations for Systemic Treatment of Atopic Dermatitis in Adults (Room 344) - Dec 22, 2022 - Abstract #AAD2023AAD_53;
Differentiate the advantages and disadvantages of available systemic treatment options for atopic dermatitis in special populations of adults, including older adults and adults with comorbidities. Recognize adverse events associated with systemic treatments for atopic dermatitis and how to monitor for and manage them.
- |||||||||| Review, Journal: Modern Interventions for Pediatric Atopic Dermatitis: An Updated Pharmacologic Approach. (Pubmed Central) - Dec 20, 2022
In this review, we discuss emerging topical and systemic (oral and injectable) treatments in pediatric AD, including topical PDE4 inhibitors and tapinarof, oral JAK inhibitors, and injected biologics including IL-4Rα inhibitor dupilumab, IL-13 inhibitor tralokinumab, IL-13Rα inhibitor lebrikizumab, IL-31Rα inhibitor nemolizumab, and IL-5Rα inhibitor benralizumab...Finally, we propose a therapeutic approach for pediatric AD that incorporates newer therapies including dupilumab and JAK inhibitors, recognizing that these agents may not be universally available or approved. Further trials that include pediatric patients, especially head-to-head studies among therapeutic classes, are needed to clarify the role of emerging treatments.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron, Blenrep (belantamab mafodotin) / GSK
Journal, Adverse events: Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management. (Pubmed Central) - Dec 17, 2022
In more severe cases, additional anti-inflammatory therapy, with corticosteroid eye drops or ointments, or topical calcineurin inhibitors-such as tacrolimus or ciclosporin-were required. Patients with resistant or refractory multiple myeloma treated with belantamab mafodotin often developed keratopathy, which could necessitate contact lens fitting, or for cycles of belantamab mafodotin to be delayed.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
3101 Atopic Dermatitis: New Insights from Bench to Bedside to Populations (Convention Center, Lobby Level, Hall 2) - Dec 5, 2022 - Abstract #AAAAI2023AAAAI_27;
It also includes clinical advances including novel therapeutics recently approved and soon to be approved, such as 3 oral JAK inhibitors and tralokinumab. Finally, it presents recommendations and new meta analytic data from a Joint Task Force on Practice Parameters workgroup which has nearly completed the Atopic Dermatitis practice parameter update, using a systematic review and Grading of Recommendations, Assessment, Development Evaluation (GRADE) analysis.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Retrospective data, Journal: Tralokinumab in the treatment of resistant atopic dermatitis: an open-label, retrospective case series study. (Pubmed Central) - Nov 22, 2022
Finally, it presents recommendations and new meta analytic data from a Joint Task Force on Practice Parameters workgroup which has nearly completed the Atopic Dermatitis practice parameter update, using a systematic review and Grading of Recommendations, Assessment, Development Evaluation (GRADE) analysis. No abstract available
|
